Lixte Biotechnology Holdings Inc. (LIXT)

[Pedro2004]

Pump and dump PR.

[Pedro2004]

Great news. Low float. And it's not running. Interesting.

[NYCJR]

warrants went on fire sale today, was able to load up close to 20k, a buy all day at these levels!

[PStockPickz]

Rockin into close

[Mamameloconto]

Avg in

[Mamameloconto]

10 plus within a week or so insiders know best 75 owned by insiders seems data will come out soon or partially and it’s super good when insiders own 75 of company trading 55m shares of 4 float new institution added weeks ago insider know what’s up

[AlphaStockNews]

Here's why $LIXT is flying! https://cnafinance.com/lixt-stock-heres-why-lixte-biotechnology-is-soaring/

[Stock Logics]

Out at $7.5. :)

[Stock Logics]

In for the pop!

[ranchhand71]

nice that lixt is not well followed but volatility past months both up and down hard to explain.

[Golden Cross]

Huge move underway

[ranchhand71]

Listing does not seem to have helped?

[Renee]

LIXT moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

LIXT: effective Nov. 20,2020 a one for 6 reverse split.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Awl416]

Talk about volatility

[Peacefulwendy]

Annual report...

http://ih.advfn.com/p.php?pid=nmona&article=70908858&symbol=LIXT

[$Pistol Pete$]

$LIXT Daily Chart

[$Pistol Pete$]

$LIXT ~ Lixte Biotechnology Holdings, Inc. due diligence report

$LIXT recent news/filings

## source: finance.yahoo.com

Wed, 03 Feb 2016 21:40:17 GMT ~ LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/160203/lixt8-k.html
*********************************************************

Wed, 03 Feb 2016 15:00:00 GMT ~ Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced that neuroscientists at the French Institute of Health and Medical Research using a mouse model of depression have identified protein phosphatase 2A as a potential ...

read full: http://finance.yahoo.com/news/lixte-biotechnology-holdings-inc-lead-150000942.html
*********************************************************

Tue, 26 Jan 2016 11:02:52 GMT ~ LIXTE BIOTECHNOLOGY HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale


read full: http://biz.yahoo.com/e/160126/lixt8-k.html
*********************************************************

Mon, 25 Jan 2016 15:30:00 GMT ~ Lixte Completes Private Placement of Convertible Preferred Stock

[Marketwired] - Lixte Biotechnology Holdings, Inc. announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common ...

read full: http://finance.yahoo.com/news/lixte-completes-private-placement-convertible-153000380.html
*********************************************************

Tue, 05 Jan 2016 01:05:00 GMT ~ Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

[PR Newswire] - EAST SETAUKET, N.Y., Jan. 5, 2016 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT) announced last week that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.

read full: http://finance.yahoo.com/news/lixte-biotechnology-holdings-inc-announces-010500168.html
*********************************************************

$LIXT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$LIXT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/LIXT/company-info
Ticker: $LIXT
OTC Market Place: OTCQB
CIK code: 0001335105
Company name: Lixte Biotechnology Holdings, Inc.
Company website: http://www.lixte.com
Incorporated In: DE, USA

Business Description: Lixte Biotechnology Holdings, Inc. is a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.Less >>



$LIXT share structure

## source: otcmarkets.com

Market Value: $11,968,954 a/o Feb 03, 2016
Shares Outstanding: 47,875,814 a/o Nov 03, 2015
Float: Not Available
Authorized Shares: 100,000,000 a/o Dec 30, 2014
Par Value: 0.001
$LIXT extra dd links

Company name: Lixte Biotechnology Holdings, Inc.
Company website: http://www.lixte.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LIXT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LIXT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LIXT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/news - http://finance.yahoo.com/q/h?s=LIXT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LIXT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LIXT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LIXT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Lixte+Biotechnology+Holdings%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Lixte+Biotechnology+Holdings%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Lixte+Biotechnology+Holdings%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.lixte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.lixte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.lixte.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LIXT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001335105&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LIXT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LIXT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LIXT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LIXT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LIXT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LIXT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LIXT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LIXT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LIXT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LIXT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LIXT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LIXT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LIXT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LIXT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LIXT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LIXT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LIXT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LIXT

[Peacefulwendy]

Here is another one I like. Long term play. Von Hoff on the SAB...

[$Pistol Pete$]

$LIXT Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depressio...

Source: Marketwired
Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

EAST SETAUKET, NY-(Marketwired - Feb 3, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016.

John S. Kovach, MD, founder and president of Lixte said, "Dr. Manuel Mameli, Inserm investigator, and Dr. Salvatore Lecca in his team at Inserm Unit 839, the Institut du Fer a Moulin, have identified increased activity in a specific region of the brain in mice showing depressive symptoms after stressful experience. This hyperactivity returns to normal after a single administration of LB-100. Dr. Mameli, in a press release from Inserm (http://presse.inserm.fr/en/treating-depressive-symptoms-from-their-roots/22124/) is quoted 'Our study unravels early cellular mechanisms able to trigger complex behavioral responses. Our study further highlights the role of the lateral habenula in the aetiology of depression. Our results provide insights on a novel potential pharmacologic target that could be studied for a therapy of mood disorders.'"

Dr. Kovach continued, "We are very interested in the findings of Dr. Mameli and his team. Their observation of rapid amelioration of the depressive symptoms by LB-100 in widely used rodent models encourages us to see if these findings translate to patients with refractory depression. As Lixte recently reported, the initial clinical study of LB-100, a Phase 1 trial in cancer patients, revealed stabilization of several types of cancer without dose-limiting toxicity, with some patients receiving LB-100 for several months. We believe a proof-of-concept clinical study of LB-100 in refractory depression is warranted. Such a trial is especially attractive because, if the results of the animal studies hold true in patients, improvement in symptoms would be expected to occur in a matter of hours rather than after weeks of treatment required by most compounds available for depressive symptoms."

"It is not surprising," Dr. Kovach added, "that a 'targeted compound' such as LB-100 which has anticancer activity would potentially have activity in non-neoplastic diseases. Many cancers have acquired genetic alterations that perturb functions of the PP2A pathway while normal tissues do not. We believe the activity of LB-100 against different types of cancer in model systems results from its targeting an already genetically disturbed PP2A pathway in the cancer but not in normal cells. Mameli and colleagues have now shown that non-genetic dysregulation of PP2A activity associated with depressive-like symptoms arises in a focal region of the brain in mice exposed to acute stress, and that targeting this abnormal PP2A function with LB-100 eliminates symptoms and restores normal PP2A activity. As altered PP2A function is known to be present in other benign diseases, there are several, if not many, potential applications of PP2A modulation to be explored."

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is completing a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCTO1837667).

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

Additional information on the Company is available at www.lixte.com.



Corporate Contact:
Eric J. Forman, Esq.
646-894-3135
[e-mail]



Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

EAST SETAUKET, NY-(Marketwired - Feb 3, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016.

John S. Kovach, MD, founder and president of Lixte said, "Dr. Manuel Mameli, Inserm investigator, and Dr. Salvatore Lecca in his team at Inserm Unit 839, the Institut du Fer a Moulin, have identified increased activity in a specific region of the brain in mice showing depressive symptoms after stressful experience. This hyperactivity returns to normal after a single administration of LB-100. Dr. Mameli, in a press release from Inserm (http://presse.inserm.fr/en/treating-depressive-symptoms-from-their-roots/22124/) is quoted 'Our study unravels early cellular mechanisms able to trigger complex behavioral responses. Our study further highlights the role of the lateral habenula in the aetiology of depression. Our results provide insights on a novel potential pharmacologic target that could be studied for a therapy of mood disorders.'"

Dr. Kovach continued, "We are very interested in the findings of Dr. Mameli and his team. Their observation of rapid amelioration of the depressive symptoms by LB-100 in widely used rodent models encourages us to see if these findings translate to patients with refractory depression. As Lixte recently reported, the initial clinical study of LB-100, a Phase 1 trial in cancer patients, revealed stabilization of several types of cancer without dose-limiting toxicity, with some patients receiving LB-100 for several months. We believe a proof-of-concept clinical study of LB-100 in refractory depression is warranted. Such a trial is especially attractive because, if the results of the animal studies hold true in patients, improvement in symptoms would be expected to occur in a matter of hours rather than after weeks of treatment required by most compounds available for depressive symptoms."

"It is not surprising," Dr. Kovach added, "that a 'targeted compound' such as LB-100 which has anticancer activity would potentially have activity in non-neoplastic diseases. Many cancers have acquired genetic alterations that perturb functions of the PP2A pathway while normal tissues do not. We believe the activity of LB-100 against different types of cancer in model systems results from its targeting an already genetically disturbed PP2A pathway in the cancer but not in normal cells. Mameli and colleagues have now shown that non-genetic dysregulation of PP2A activity associated with depressive-like symptoms arises in a focal region of the brain in mice exposed to acute stress, and that targeting this abnormal PP2A function with LB-100 eliminates symptoms and restores normal PP2A activity. As altered PP2A function is known to be present in other benign diseases, there are several, if not many, potential applications of PP2A modulation to be explored."

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is completing a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCTO1837667).

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

Additional information on the Company is available at www.lixte.com.



Corporate Contact:
Eric J. Forman, Esq.
646-894-3135
[e-mail]





Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

EAST SETAUKET, NY-(Marketwired - Feb 3, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016.

John S. Kovach, MD, founder and president of Lixte said, "Dr. Manuel Mameli, Inserm investigator, and Dr. Salvatore Lecca in his team at Inserm Unit 839, the Institut du Fer a Moulin, have identified increased activity in a specific region of the brain in mice showing depressive symptoms after stressful experience. This hyperactivity returns to normal after a single administration of LB-100. Dr. Mameli, in a press release from Inserm (http://presse.inserm.fr/en/treating-depressive-symptoms-from-their-roots/22124/) is quoted 'Our study unravels early cellular mechanisms able to trigger complex behavioral responses. Our study further highlights the role of the lateral habenula in the aetiology of depression. Our results provide insights on a novel potential pharmacologic target that could be studied for a therapy of mood disorders.'"

Dr. Kovach continued, "We are very interested in the findings of Dr. Mameli and his team. Their observation of rapid amelioration of the depressive symptoms by LB-100 in widely used rodent models encourages us to see if these findings translate to patients with refractory depression. As Lixte recently reported, the initial clinical study of LB-100, a Phase 1 trial in cancer patients, revealed stabilization of several types of cancer without dose-limiting toxicity, with some patients receiving LB-100 for several months. We believe a proof-of-concept clinical study of LB-100 in refractory depression is warranted. Such a trial is especially attractive because, if the results of the animal studies hold true in patients, improvement in symptoms would be expected to occur in a matter of hours rather than after weeks of treatment required by most compounds available for depressive symptoms."

"It is not surprising," Dr. Kovach added, "that a 'targeted compound' such as LB-100 which has anticancer activity would potentially have activity in non-neoplastic diseases. Many cancers have acquired genetic alterations that perturb functions of the PP2A pathway while normal tissues do not. We believe the activity of LB-100 against different types of cancer in model systems results from its targeting an already genetically disturbed PP2A pathway in the cancer but not in normal cells. Mameli and colleagues have now shown that non-genetic dysregulation of PP2A activity associated with depressive-like symptoms arises in a focal region of the brain in mice exposed to acute stress, and that targeting this abnormal PP2A function with LB-100 eliminates symptoms and restores normal PP2A activity. As altered PP2A function is known to be present in other benign diseases, there are several, if not many, potential applications of PP2A modulation to be explored."

About Lixte Biotechnology Holdings, Inc.

Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is completing a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCTO1837667).

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

Additional information on the Company is available at www.lixte.com.



Corporate Contact:
Eric J. Forman, Esq.
646-894-3135
[e-mail]

[Peacefulwendy]

Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

EAST SETAUKET, NY-(Marketwired - Feb 3, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that neuroscientists at the French Institute of Health and Medical Research (Inserm) using a mouse model of depression have identified protein phosphatase 2A (PP2A) as a potential pharmacological target for therapy. Administration of LB-100, Lixte's proprietary inhibitor of PP2A, rapidly reduced depressive-like symptoms in these conditioned animals. The findings were published in the journal Nature Medicine on January 25th, 2016.

John S. Kovach, MD, founder and president of Lixte said, "Dr. Manuel Mameli, Inserm investigator, and Dr. Salvatore Lecca in his team at Inserm Unit 839, the Institut du Fer a Moulin, have identified increased activity in a specific region of the brain in mice showing depressive symptoms after stressful experience. This hyperactivity returns to normal after a single administration of LB-100. Dr. Mameli, in a press release from Inserm (http://presse.inserm.fr/en/treating-depressive-symptoms-from-their-roots/22124/) is quoted 'Our study unravels early cellular mechanisms able to trigger complex behavioral responses. Our study further highlights the role of the lateral habenula in the aetiology of depression. Our results provide insights on a novel potential pharmacologic target that could be studied for a therapy of mood disorders.'"

Dr. Kovach continued, "We are very interested in the findings of Dr. Mameli and his team. Their observation of rapid amelioration of the depressive symptoms by LB-100 in widely used rodent models encourages us to see if these findings translate to patients with refractory depression. As Lixte recently reported, the initial clinical study of LB-100, a Phase 1 trial in cancer patients, revealed stabilization of several types of cancer without dose-limiting toxicity, with some patients receiving LB-100 for several months. We believe a proof-of-concept clinical study of LB-100 in refractory depression is warranted. Such a trial is especially attractive because, if the results of the animal studies hold true in patients, improvement in symptoms would be expected to occur in a matter of hours rather than after weeks of treatment required by most compounds available for depressive symptoms."

"It is not surprising," Dr. Kovach added, "that a 'targeted compound' such as LB-100 which has anticancer activity would potentially have activity in non-neoplastic diseases. Many cancers have acquired genetic alterations that perturb functions of the PP2A pathway while normal tissues do not. We believe the activity of LB-100 against different types of cancer in model systems results from its targeting an already genetically disturbed PP2A pathway in the cancer but not in normal cells. Mameli and colleagues have now shown that non-genetic dysregulation of PP2A activity associated with depressive-like symptoms arises in a focal region of the brain in mice exposed to acute stress, and that targeting this abnormal PP2A function with LB-100 eliminates symptoms and restores normal PP2A activity. As altered PP2A function is known to be present in other benign diseases, there are several, if not many, potential applications of PP2A modulation to be explored."

[Peacefulwendy]

Lixte Completes Private Placement of Convertible Preferred Stock

Lixte Biotechnology Holdings, Inc. (QB) (USOTC:LIXT)

Today : Monday 25 January 2016

EAST SETAUKET, NY-(Marketwired - Jan 25, 2016) - Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common shares at a per share price of $0.80.

Lixte's CEO, John S. Kovach, M.D., said, "This new investment allows Lixte to pursue opportunities that have emerged regarding our lead anticancer compound, LB-100.

First, in the Phase I trial, several solid tumor patients with a variety of recurrent progressive cancers had stabilization of their disease in the absence of dose-limiting toxicity as reported at the 2015 AACR-NCI-EORTC International Conference in Boston. We had not anticipated that LB-100 alone would stop tumor progression in some solid tumor patients. This finding raises opportunities, currently being explored, to go directly to Phase 2 studies of LB-100 as a single agent.

Second, Lixte has licensed LB-100 to the Taipei Medical University to determine the activity of LB-100 plus doxorubicin in Asian patients with hepatocellular cancer, beginning with a Phase 1b/2 trial planned to start this summer. This will test the ability of LB-100, demonstrated in several animal models, to enhance the effectiveness of a widely used anticancer drug against one of the most common and devastating cancers worldwide.

Third, scientists at the National Institutes of Health (NIH) reported that LB-100 enhances the anti-tumor activity of cisplatin and reduced cisplatin-resistance of human medulloblastoma cells in animal models. Previously, NIH investigators found that LB-100 enhanced the activity of cisplatin in models of cisplatin sensitive and cisplatin-resistant human ovarian cancer."

Dr. Kovach continued, "Because of these new developments, Lixte is considering several options for Phase 1b/2 trials, with recurrent platinum-resistant ovarian cancer at the top of the list. The most definitive trial design would be a randomized study of LB-100 plus a platinum compound versus the therapeutic choice of the treating doctor with an opportunity for those failing treatment with the 'physician's choice' to receive the LB-100 regimen. The cost of a randomized trial would require additional financial resources beyond those of the private placement."

[Peacefulwendy]

Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

SOURCE Lixte Biotechnology Holdings, Inc.

EAST SETAUKET, N.Y., Dec. 30, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that it has granted an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia to Taipei Medical University (TMU). LB-100 is not currently approved for treatment of HCC. Under the license, Taipei Medical University will determine the effectiveness of LB-100 against HCC in clinical trials conducted in compliance with both Taiwanese and American regulatory requirements. TMU will pay milestone and royalty payments to Lixte. Both parties recognize that development of improved therapy for HCC has been very challenging and that success cannot be guaranteed.

John S. Kovach M.D., founder and president of Lixte, said "LB-100 is a novel small molecule that in preclinical studies has activity against a number of different cancer types alone and, most prominently, in combination with cytotoxic drugs, including some known to be active against hepatocellular carcinoma. We welcome an opportunity to work with an outstanding group of investigators in Taiwan to assess the value of LB-100 against this all-too-common and devastating cancer."

HCC is the fifth most common cancer and third most common cause of cancer deaths worldwide, with the majority of those deaths in Asia. The World Cancer Research Fund International reported that 782,000 new cases were diagnosed in 2012 worldwide. There are approximately 35,000 new cases and 24,000 deaths from HCC annually in the US according to the National Cancer Institute.

Taipei Medical University has nine colleges, thirteen undergraduate schools, fifteen graduate institutes, as well as three affiliated hospitals with approximately three thousand beds. TMU is one of the largest health care systems in Taipei, providing teaching, research and clinical services. In 2012 they established the Taipei Cancer Center, the first world-class cancer center in Taiwan, combining cancer research, training and clinical treatment, dedicated to providing the full spectrum of services for adult and pediatric oncology.

http://www.newson6.com/story/30852953/lixte-biotechnology-holdings-inc-announces-exclusive-licensing-of-their-lead-anti-cancer-compound-lb-100-for-potential-treatment-of-hepatocellular

[Peacefulwendy]

http://ih.advfn.com/p.php?pid=nmona&article=69254320

[Peacefulwendy]

Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity

EAST SETAUKET, N.Y., Nov. 6, 2015 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today that in an ongoing Phase I trial its lead anti-cancer compound, LB-100, was associated with stabilization of a variety of advanced cancers that had been progressing despite extensive prior treatment. The results were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, on November 6. The authors were Vincent Chung, City of Hope, Duarte, CA; Donald Richards, Texas Oncology, Tyler, TX; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; John S. Kovach, Lixte Biotechnology Holdings, Inc., East Setauket, NY; Aaron Scott Mansfield, Mayo Clinic, Rochester, MN.

A total of 21 patients received LB-100 for 3-consecutive days in 3-week cycles. Nine of these patients had stabilization of their disease without significant toxicity. One patient with pancreatic cancer received 14 cycles of LB-100 (42 weeks); one with thymoma, 9 cycles; one with testicular and one with carcinoid of the lung, 5 cycles; two with ovarian, 3 and 6 cycles; and one with NSCLC and one with duodenal cancer, 3 cycles. The average number of cycles received at the last four evaluable dose levels of LB-100 was 4.8 (14.4 weeks). In a study by Mansfield et al (2015 JCO 33[15] suppl:2567), the average number of cycles of a new drug in 51 NCI-sponsored Phase 1 trials conducted from 1994-2014 involving 1841 patients was 2.0 (6-8 weeks).

John S. Kovach M.D., founder and president of Lixte, said "Lixte interprets the results as showing that LB-100 has single agent activity in suppressing the growth of several types of cancer. What is highly encouraging is that stabilization of disease occurred in the absence of dose-limiting toxicity. In fact, most patients tolerated repeated doses without any ill-effects. As pre-clinical studies have shown that LB-100 potentiates the effectiveness of cytotoxic agents, we believe that LB-100 alone and in combination with standard anti-cancer drugs and/or radiation may offer new therapeutic options for a spectrum of neoplastic diseases."

About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the Company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is in a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCT01837667).

Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

Additional information on the Company is available at www.lixte.com.

Corporate Contact:
Eric J. Forman, Esq.
646-894-3135
[e-mail]

SOURCE Lixte Biotechnology Holdings

[kranthikumar]

LIXT is up by 100%

[kranthikumar]

LIXT is smells like a winner

[kranthikumar]

LIXT is already crossed 100%.now at 120%

[dan5000ny]

Took a position in LIXT, see what happens